Wilson, Jonathan E. published the artcileDiscovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes, SDS of cas: 1008506-24-8, the publication is Bioorganic & Medicinal Chemistry Letters (2016), 26(12), 2947-2951, database is CAplus and MEDLINE.
A novel series of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists are described. The series was designed to address the suboptimal PK (pharmacokinetic) and off-target profile of a class of N-aryl-benzo-[1,4]-oxazepine-4-carboxamides that were identified from a high-throughput screen of the Merck compound collection for GPR142 agonists. This work led to the discovery of 3-phenoxy-benzo-[1,2,4]-triazolo-[1,4]-oxazepine I, a potent GPR142 agonist with an off-target and PK profile suitable for in vivo studies. This compound and a related analog II were shown to be active in mouse oral glucose tolerance tests (OGTTs). Furthermore, a GPR142 knock-out mouse OGTT study with compound II provides evidence that its glucose-lowering effect is mediated by GPR142.
Bioorganic & Medicinal Chemistry Letters published new progress about 1008506-24-8. 1008506-24-8 belongs to pyridine-derivatives, auxiliary class Pyridine,Boronic acid and ester,Ether,Pyridine,Boronic Acids,Boronic acid and ester, name is 3-Methoxypyridine-4-boronic acid, and the molecular formula is C9H13NO2, SDS of cas: 1008506-24-8.
Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem